Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

Dear Common Dreams Readers:
Corporations and billionaires have their own media. Shouldn't we? When you “follow the money” that funds our independent journalism, it all leads back to this: people like you. Our supporters are what allows us to produce journalism in the public interest that is beholden only to people, our planet, and the common good. Please support our Mid-Year Campaign so that we always have a newsroom for the people that is funded by the people. Thank you for your support. --Jon Queally, managing editor

Join the small group of generous readers who donate, keeping Common Dreams free for millions of people each year. Without your help, we won’t survive.

"Shock of all shocks: It turns out that President Trump was not being honest when he said he was going to stop the prescription drug companies from 'getting away with murder.' Another day. Another lie," wrote Sen. Bernie Sanders in response to Trump's plan. (Photo: Youtube/Screengrab)

Trump's "Pharma-Friendly" Drug Plan Denounced as Doing Little or Nothing to Lower Prices

"How the heck is this going to lower drug prices in this country?"

Jake Johnson

Officially ditching his campaign promise to challenge the pharmaceutical industry head-on and allow Medicare to negotiate lower drug prices—a betrayal that may have something to do with the fact that the White House is currently occupied by former Big Pharma executives in key posts—President Donald Trump on Friday formally unveiled a plan ostensibly aimed at cutting medicine costs that analysts and progressive critics are already slamming as wholly inadequate and "pharma-friendly."

"Trump is proposing to increase drug prices abroad, probably through trade deals. This is the biggest item on Big Pharma's wish list! How the heck is this going to lower drug prices in this country?"
—Topher Spiro, Center for American Progress

Taking heat off the greedy pharmaceutical companies he once accused of "getting away with murder," Trump's plan shifts much of the blame for soaring drug prices in America on foreign governments that "use socialized healthcare to command unfairly low prices from U.S. drugmakers," according to a summary of Trump's proposals obtained by the New York Times.

Sen. Bernie Sanders (I-Vt.), who last October introduced legislation that would allow Medicare to negotiate drug prices, denounced Trump's plan as "lukewarm" and said approaches that don't directly take on the price-gouging of American drugmakers "just aren't going to work."

Rather than allowing the government to negotiate lower drug prices—a proposal backed by 92 percent of Americans—Trump's plan vaguely promises to "encourage innovation" in the private sector while pursuing "reforms" to Medicare to promote "greater flexibility."

"There is nothing, absolutely nothing in here to lower drug prices for the 150 million Americans with employer coverage or the millions more with other private insurance," Topher Spiro, a senior fellow at the Center for American Progress, wrote after reviewing the summary of Trump's plan.

Spiro also noted that the plan would do nothing to reduce the "sky-high" costs of specialty drugs.

While Trump's plan won't provide relief for hundreds of millions harmed by astronomical drug prices, Spiro added that it does fulfill "the biggest item on Big Pharma's wish list":

A Public Citizen report (pdf) released on Friday ahead of Trump's long-delayed drug policy unveil may provide some clues into why the president has decided to reward the U.S. pharmaceutical industry instead of taking the tough stance he promised on the campaign trail.

"We expect President Trump's upcoming speech on lowering drug prices to be rhetorically critical of pharmaceutical manufacturers and the supply chain, but he will not propose actions that actually threaten drugmakers' ability to set high prices for their product." 
—Andrea Harris, Height Capital Markets

Titled "Big Pharma Swamps Trump," the report shows "the pharmaceutical industry spent $279 million on lobbying the Trump administration and Congress" in 2017—"a record amount."

"Solutions to Big Pharma's monopoly abuses are at hand, but they require a political will that we are unlikely to see from an administration in the grip of the drug corporations," Public Citizen president Robert Weissman said in a statement.

Thanks to the enormous clout of drug companies have within the Trump administration and the GOP-controlled Congress, pharmaceutical industry analysts said openly ahead of Trump's speech on Friday that they aren't worried the president will do anything to harm the profits of drugmakers.

"We expect President Trump's upcoming speech on lowering drug prices to be rhetorically critical of pharmaceutical manufacturers and the supply chain, but he will not propose actions that actually threaten drugmakers' ability to set high prices for their product," Height Capital Markets analyst Andrea Harris said in an interview with MarketWatch on Friday.

Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

Just a few days left in our crucial Mid-Year Campaign and we might not make it without your help.
Who funds our independent journalism? Readers like you who believe in our mission: To inform. To inspire. To ignite change for the common good. No corporate advertisers. No billionaire founder. Our non-partisan, nonprofit media model has only one source of revenue: The people who read and value this work and our mission. That's it.
And the model is simple: If everyone just gives whatever amount they can afford and think is reasonable—$3, $9, $29, or more—we can continue. If not enough do, we go dark.

All the small gifts add up to something otherwise impossible. Please join us today. Donate to Common Dreams. This is crunch time. We need you now.

'Witness Intimidation. Clear as Day': Jan. 6 Panel Teases Evidence of Cover-Up Effort

"Add witness tampering to the laundry list of crimes Trump and his allies must be charged with," said professor Robert Reich.

Jessica Corbett ·

'Bombshell After Bombshell' Dropped as Jan. 6 Testimony Homes In On Trump Guilt

"Hutchinson's testimony of the deeply detailed plans of January 6 and the inaction of those in the White House in response to the violence show just how close we came to a coup," said one pro-democracy organizer.

Brett Wilkins ·

Mark Meadows 'Did Seek That Pardon, Yes Ma'am,' Hutchinson Testifies

The former aide confirmed that attorney Rudy Giuliani also sought a presidential pardon related to the January 6 attack.

Jessica Corbett ·

UN Chief Warns of 'Ocean Emergency' as Leaders Confront Biodiversity Loss, Pollution

"We must turn the tide," said Secretary-General António Guterres. "A healthy and productive ocean is vital to our shared future."

Julia Conley ·

'I Don't F—ing Care That They Have Weapons': Trump Wanted Security to Let Armed Supporters March on Capitol

"They're not here to hurt me," Trump said on the day of the January 6 insurrection, testified a former aide to ex-White House Chief of Staff Mark Meadows.

Jake Johnson ·

Common Dreams Logo